…
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Available public filings identify Aspire BioPharma, Inc. (ASBP) as a small Nasdaq-listed specialty pharmaceutical company. Its long-term prospects appear to depend on progress of any development-stage assets, licensing or partnership deals, and access to capital that could support commercialization. Investors may find potential upside if clinical or strategic milestones are reached and disclosure improves.
Major risks include thin trading liquidity, dependence on external financing, unproven product candidates and regulatory and execution uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -24.48M | -12.54M | 4.46M | 3.34M | -0.03M |
| Net income | -24.48M | -12.54M | 4.46M | 3.34M | -0.03M |
| Selling general administrative | 17.64M | 3.09M | 1.34M | 0.98M | 0.03M |
| Selling and marketing expenses | 0.79M | 0.13M | 0.04M | 0.05M | - |
| Gross profit | -0.00M | 0.00M | 0.00M | 0.00M | - |
| Reconciled depreciation | - | 0.00M | 0.00M | 0.00M | - |
| Ebit | - | -1.21M | 4.46M | -0.60M | -0.05M |
| Ebitda | -19.35M | -11.65M | 5.80M | 3.34M | -0.03M |
| Depreciation and amortization | - | - | 1.34M | - | 0.03M |
| Operating income | -19.35M | -3.09M | -1.34M | -0.98M | -0.03M |
| Other operating expenses | 19.36M | 3.09M | 1.34M | 0.98M | 0.03M |
| Interest expense | 8.53M | 0.89M | 0.01M | 0.00M | - |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Interest income | - | 0.55M | 5.81M | - | - |
| Net interest income | -8.53M | -0.34M | 5.80M | 0.00M | - |
| Income tax expense | - | 0.00M | 0.00M | 0.00M | - |
| Total revenue | 0.01M | 0.00M | 0.00M | 0.00M | - |
| Total operating expenses | 19.35M | 3.09M | 1.34M | 0.98M | 0.03M |
| Cost of revenue | 0.01M | 0.00M | 0.00M | 0.00M | - |
| Total other income expense net | -5.13M | -9.45M | 5.80M | 4.32M | 0.00M |
| Net income from continuing ops | -24.48M | -12.54M | -0.36M | -0.60M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1.31M | 0.15M | 19.98M | 300.18M | 0.29M |
| Other current assets | 0.06M | 0.11M | 0.07M | 0.60M | 0.29M |
| Total liab | 7.69M | 1.69M | 0.40M | 11.12M | 0.29M |
| Total stockholder equity | -6.38M | -1.54M | 19.58M | 289.07M | -0.00M |
| Other current liab | 5.19M | 0.11M | 0.24M | 0.09M | 0.05M |
| Common stock | 0.00M | 0.17M | 19.90M | 299.00M | 0.00M |
| Capital stock | 0.00M | 0.02M | 0.22M | 0.22M | - |
| Retained earnings | -27.26M | -2.78M | -11.29M | -9.94M | -0.03M |
| Other assets | - | - | - | - | -0.29M |
| Cash | 1.00M | 0.00M | 0.01M | 0.50M | - |
| Total current liabilities | 7.59M | 1.69M | 0.40M | 0.30M | 0.29M |
| Current deferred revenue | - | - | - | 0.00M | - |
| Net debt | 0.38M | 1.26M | 0.01M | -0.50M | 0.24M |
| Short term debt | 1.38M | 1.27M | 0.01M | 0.03M | 0.24M |
| Short long term debt | 5.18M | 1.27M | 0.36M | 0.03M | - |
| Short long term debt total | 1.38M | 1.27M | 0.01M | 0.03M | 0.24M |
| Other stockholder equity | 20.88M | 1.22M | 10.96M | 0.76M | 0.02M |
| Total current assets | 1.31M | 0.15M | 0.08M | 1.10M | 0.29M |
| Net receivables | - | 0.04M | - | - | - |
| Inventory | 0.25M | 0.00M | - | - | - |
| Accounts payable | 1.01M | 0.31M | 0.15M | 0.18M | 0.00M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Non currrent assets other | - | -6.67M | -24.87M | 298.79M | 0.29M |
| Non current assets total | 0.00M | 6.67M | 19.90M | 299.08M | 0.29M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | -0.08M | -4.90M | - |
| Total cashflows from investing activities | - | 13.78M | 284.92M | -294.69M | - |
| Net borrowings | 6.57M | 0.00M | - | - | - |
| Total cash from financing activities | 5.92M | 0.26M | -284.76M | 296.59M | 0.00M |
| Net income | -24.48M | -1.31M | 4.46M | 3.34M | -0.00M |
| Change in cash | 1.00M | -0.01M | -0.50M | 0.50M | - |
| Begin period cash flow | 0.00M | 0.01M | 0.50M | 0.19M | - |
| End period cash flow | 1.00M | 0.00M | 0.01M | 0.50M | 0.19M |
| Total cash from operating activities | -4.92M | -0.27M | -0.65M | -1.41M | -0.00M |
| Issuance of capital stock | 0.27M | 0.26M | 0.00M | 1.00M | - |
| Depreciation | 8.02M | 0.00M | 0.00M | 0.00M | - |
| Other cashflows from investing activities | - | -13.78M | 284.92M | -289.79M | - |
| Change to inventory | -0.25M | 0.00M | - | - | - |
| Change to account receivables | - | -0.04M | - | 0.40M | - |
| Sale purchase of stock | - | -13.78M | -284.92M | - | - |
| Other cashflows from financing activities | -0.91M | 11.98M | - | -0.30M | 0.00M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.53M | 1.03M | 0.69M | -0.43M | -0.00M |
| Stock based compensation | 14.13M | 0.00M | - | - | - |
| Other non cash items | -3.13M | 0.01M | -5.80M | -4.32M | 0.00M |
| Free cash flow | -4.92M | -0.27M | -0.65M | -1.41M | -0.00M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| ASBP Aspire BioPharma, Inc. |
0.10 1.20% |
8.40 | - | - | 159.42 | - | 831.28 |
| NVO Novo Nordisk A/S |
-0.64 1.57% |
40.06 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 |
| VRTX Vertex Pharmaceuticals Inc |
8.09 1.51% |
542.29 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 |
| REGN Regeneron Pharmaceuticals Inc |
2.85 0.30% |
960.62 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 |
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
| Name | Title | Year Born |
|---|---|---|
| Mr. Kraig T. Higginson | Interim CEO, President & Executive Chairman of the Board | 1956 |
| Mr. Ernest J. Scheidemann Jr. | Chief Financial Officer | 1961 |
| Mr. Stephen E. Quesenberry | General Counsel & Corporate Secretary | 1964 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.